The group's principal activities are to develop, manufacture and market medical devices for the treatment of urological disorders. The group offers non-surgical, catheter-based therapies that use a proprietary cooled microwave technology known as cooled thermotherapy for the treatment of benign prostatic hyperplasia (bph). The cooled thermotherapy can be performed without anesthesia or intravenous sedation and can be performed in a physician's office or an outpatient clinic. The therapy provides a safe and cost-effective solution that is superior to medication without the complications and side effects inherent in surgical procedures. The products of the group are marketed under the names targis (TM) and prostatron (r). The group operates in the United States, Europe and Asia.
